首页> 外文期刊>Lung cancer: Journal of the International Association for the Study of Lung Cancer >Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.
【24h】

Defective expression of transforming growth factor beta type II receptor (TGFBR2) in the large cell variant of non-small cell lung carcinoma.

机译:非小细胞肺癌大细胞变体中转化生长因子βII型受体(TGFBR2)的缺陷表达。

获取原文
获取原文并翻译 | 示例
           

摘要

Large cell carcinoma (LCC) of the lung is defined as an undifferentiated carcinoma without the characteristic features of squamous cell (SqC), small cell, or adenocarcinomas (AdC). In the present study, the expression level of the important tumor suppressor, transforming growth factor beta type II receptor (TGFBR2), was examined both in LCC and non-LCC tumors, which include AdC, SqC and adenosquamous carcinoma (Ad-SqC). Immunohistochemical staining with TGFBR2 antibody revealed statistically significant or near significant differences in the reduced expression in LCC (80% of cases) versus AdC (42.1% of cases, P=0.0288) and SqC (47.1% of cases, P=0.0589), or LCC versus non-LCC (45% of cases, P=0.02). The differences in the expression level of TGFBR2 between LCC and non-LCC were consistent with the histopathologic classification of these tumors, suggesting that the defective TGFBR2 expression might contribute to the carcinogenesis and/or development of LCC.
机译:肺大细胞癌(LCC)被定义为没有鳞状细胞(SqC),小细胞或腺癌(AdC)的特征的未分化癌。在本研究中,在LCC和非LCC肿瘤(包括AdC,SqC和腺鳞癌(Ad-SqC))中都检查了重要的肿瘤抑制因子转化生长因子βII型受体(TGFBR2)的表达水平。用TGFBR2抗体进行的免疫组织化学染色显示LCC(80%的病例)与AdC(42.1%的病例,P = 0.0288)和SqC(47.1%的病例,P = 0.0589)的表达降低具有统计学显着或接近显着差异LCC与非LCC(45%的病例,P = 0.02)。 LCC和非LCC之间TGFBR2表达水平的差异与这些肿瘤的组织病理学分类一致,表明TGFBR2表达缺陷可能有助于LCC的癌变和/或发展。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号